NYSE:MAC
NYSE:MACRetail REITs

Macerich (MAC): Losses Worsen 10.4% Annually, Margin Recovery Draws Focus Heading Into Earnings

Macerich (MAC) remains unprofitable as net losses have expanded at an average rate of 10.4% per year over the past five years, and margin performance is yet to show improvement. Revenue growth is projected at just 1.8% per year, lagging well behind the broader US market’s pace of 10.5%. Despite these challenges, earnings are forecast to surge 89.5% per year with a return to profitability expected within the next three years. This outlook has drawn investor attention, especially with the share...
NYSE:DIN
NYSE:DINHospitality

Dine Brands Global (DIN): Net Profit Margin Drops to 5.3%—Profitability Slide Challenges Bullish Narratives

Dine Brands Global (DIN) posted a net profit margin of 5.3%, down from 10.9% a year ago. Although the company has averaged an impressive 28.9% annual earnings growth over the past five years, the most recent year bucked that trend with negative growth, and revenue is forecast to inch up at just 1.5% per year, which is well behind the US market’s 10.5% pace. For investors, the story right now is one of shrinking margins and muted near-term growth. However, value-focused buyers may see...
NasdaqGM:BETR
NasdaqGM:BETRDiversified Financial

Will BETR’s New Marketing Leadership Accelerate Its Digital Disruption Ambitions in the Mortgage Industry?

Earlier this month, NEO Home Loans announced the appointment of Bri Lees as Head of Marketing to drive brand strategy and deepen integration between its advisor network and Better Home & Finance's digital mortgage platform. This leadership move underscores the company's commitment to scaling its technology-driven approach at a time when industry voices are drawing attention to its transformational ambitions. We’ll explore how the endorsement from activist investor Eric Jackson highlights...
NasdaqGS:CTMX
NasdaqGS:CTMXBiotechs

CytomX Therapeutics (CTMX): Assessing Valuation After New CX-801 Data Highlights Immune Activation in Melanoma

CytomX Therapeutics (CTMX) has drawn fresh attention after announcing plans to share initial translational and biomarker data for CX-801 at the Society for Immunotherapy of Cancer Annual Meeting. This reveal highlights immune activation in advanced melanoma and furthers the company's oncology ambitions. See our latest analysis for CytomX Therapeutics. Recent excitement around CytomX Therapeutics isn’t just about their upcoming clinical data. The stock’s momentum is hard to miss. Shares have...
NYSE:BRSL
NYSE:BRSLHospitality

Brightstar Lottery Valuation in Focus After Expansion News and Recent 7.5% Price Drop

Wondering if Brightstar Lottery offers real value for your portfolio? Let’s take a closer look at what’s happening beneath the surface to see if now might be the right entry point. The shares have been in the spotlight lately, rising just 0.1% over the past week but dropping 7.5% over the last month, with a 5-year return that is still an impressive 133.5%. Recent headlines highlight the company’s expansion into new markets, which has caught the attention of both investors and industry...
NasdaqGS:GT
NasdaqGS:GTAuto Components

Goodyear (GT) Deep Value Persists as Losses Rise 1.8% Annually, Challenging Turnaround Narratives

Goodyear Tire & Rubber (GT) delivered a 1.8% per year increase in losses over the past five years, highlighting persistent unprofitability. Revenue is forecast to rise just 0.6% a year, trailing the broader U.S. market's expected 10.4% annual growth. While profitability is still out of reach, the company is projected to rebound sharply with earnings growth of 94.05% per year, potentially achieving profitability within the next three years. See our full analysis for Goodyear Tire & Rubber. The...